Carcinogenic risk of bath PUVA in comparison to oral PUVA therapy

Dermatology

Volumn 199, Issue 2, 1999, Pages 106-112

  Shephard, S E ^a   Panizzon, R G ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

METHOXSALEN; TRIMETHYLPSORALEN;

BATH; CANCER RISK; DOSE RESPONSE; DRUG TISSUE LEVEL; HUMAN; NOTE; ORAL DRUG ADMINISTRATION; PHOTOCHEMISTRY; PRIORITY JOURNAL; PSORIASIS; PUVA; SKIN CANCER; TOPICAL DRUG ADMINISTRATION; ULTRAVIOLET A RADIATION;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; BATHS; DNA ADDUCTS; FEMALE; HUMANS; LYMPHOMA, T-CELL, CUTANEOUS; MALE; METHOXSALEN; MUTAGENESIS; PHOTOSENSITIZING AGENTS; PSORIASIS; PUVA THERAPY; SKIN DISEASES; SKIN NEOPLASMS; SUBCELLULAR FRACTIONS; TRIOXSALEN; VITILIGO;

EID: 0032695818     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000018215     Document Type: Note

References (29)

1. Lauharanta J: Photochemotherapy. Clin Dermatol 1997;15:769-780.
2. Lowe N, Chizhevsky V, Gabriel H: Photo(chemo)therapy: General principles. Clin Dermatol 1997;15:745-752.
3. Lüftl M, Degitz K, Plewig G, Röcken M: Psoralen bath plus UV-A therapy: Possibilities and limitations. Arch Dermatol 1997;133:1597-1603.
4. IARC: 8-Methoxypsoralen (methoxsalen) plus ultraviolet radiation (group 1). IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Lyon, International Agency Research Cancer, 1987; Suppl 7, pp 243-245.
5. Stern R, Laird N: The carcinogenic risk of treatments for severe psoriasis. Cancer 1994;73: 2759-2764.
6. Mai D, Omohundro C, Dijkstra J, Bailin P: Childhood vitiligo successfully treated with bath PUVA. Pediatr Dermatol 1998;15:53-55.
7. Lindelöf B, Sigurgeirsson B, Tegner E, Larkö O, Berne B: Comparison of the carcinogenic potential of trioxsalen bath PUVA and oral methoxsalen PUVA. Arch Dermatol 1992; 128: 1341-1344.
8. Hannuksela A, Pukkala E, Hannuksela M, Karvonen J: Cancer incidence among Finnish patients with psoriasis treated with trioxsalen bath PUVA. J Am Acad Dermatol 1996;35: 685-689.
9. Berne B, Fischer T, Michaëlsson G, Norén P: Long-term safety of trioxsalen bath PUVA treatment: An 8-year follow-up of 149 psoriasis patients. Photodermatology 1984;1:18-22.
10. Lindelöf B, Sigurgeirsson B, Tegner E. Larkö O, Johannesson A, Berne B, Cristensen O, Andersson T, Törngren M. Molin L, Nylander-Lundqvist E, Emtestam L: PUVA and cancer: A large-scale epidemiological study. Lancet 1991;338:91-93.
11. McKenna K, Patterson C, Handley J, McGinn S, Allen G: Cutaneous neoplasia following PUVA therapy for psoriasis. Br J Dermatol 1996;1334:639-642.
12. Lever L, Farr P: Skin cancers or premalignant lesions occur in half of high-dose PUVA patients. Br J Dermatol 1994;131:215-219.
13. Maier H, Schemper M, Ortel B, Binder M, Tanew A, Hönigsmann H: Skin tumors in photochemotherapy for psoriasis: A single-center follow-up of 496 patients. Dermatology 1996; 193:185-191.
14. Studniberg H, Weller P: PUVA, UVB, psoriasis, and nonmelanoma skin cancer. J Am Acad Dermatol 1993;29:1013-1022.
15. Gold L, Sawyer C, Magaw R, Backman G, de Veciana M, Levinson R, Hooper N, Havender W, Bernstein L, Peto R, Pike M, Ames B: A carcinogenic potency database of the standardized results of animal bioassays. Environ Health Perspect 1984;58:9-319.
16. Gomez M, Azana J, Arranz I, Harto A, Ledo A: Plasma levels of 8-methoxypsoralen after bath-PUVA for psoriasis: Relationship to disease severity. Br J Dermatol 1995;131:37-40.
17. Huuskonen H, Koulu L, Wilén G: Quantitative determination of methoxsalen in human serum, suction blister fluid and epidermis by gas chromatography mass spectrometry. Photodermatology 1984;1:137-140.
18. Thomas S, O'Sullivan J, Balac N: Plasma levels of 8-methoxypsoralen following oral or bath-water treatment. Br J Dermatol 1991;125: 56-58.
19. Stolk L, Siddiqui A: Biopharmaceutics, pharmacokinetics and pharmacology of psoralens. Gen Pharmacol 1988; 19:649-653.
20. Stern R, Vakeva L: Noncutaneous malignant tumors in the PUVA follow-up study: 1975-1996. J Invest Dermatol 1997;108:897-900.
21. Schempp C, Schöpf E, Simon J: Phototesting in bath-PUVA: Marked reduction of 8-methoxypsoralen (8-MOP) activity within one hour after an 8-MOP bath. Photodermatol Photoimmunol Photomed 1996;12:100-102.
22. Degitz K, Plewig G, Röcken M: Rapid decline in photosensitivily after 8-methoxypsoralen bathwater delivery. Arch Dermatol 1996;132: 1394-1395.
23. Humbert P. Treffel P, Makki S, Millet J, Agache P: Peak blistering point: Influence on fluid levels of 5-MOP in human skin in vivo after systemic administration. Arch Dermatol Res 1991;283:297-299.
24. Malane M, Gasparro F: T cell molecular targets for psoralens. Ann NY Acad Sci 1991;636: 196-208.
25. Beaumont P, Land E, Navaratnam S, Parsons B, Phillips G: A pulse radiolysis study of the complexing of furocoumarins with DNA and proteins. Biochim Biophys Acta 1980;608:182-189.
26. Schmitz S, Garbe C, Tebbe B, Orfanos C: Langwellige ultraviolette Strahlung (UVA) und Hautkrebs. Hautarzt 1994;45:517-525.
27. Berg R, de Gruijl F, van der Leun J: Interaction between ultraviolet A and ultraviolet B radiations in skin cancer induction in hairless mice. Cancer Res 1993;53:4212-4217.
28. Schmitt I, Maxwell V, Olack G, Edelson R, Chimenti S, Gasparro F: The specific effects of 8-methoxypsoralen photoadducts on cell growth: HPLC analysis of monoadduct and crosslink formation in cells exposed to split-dose treatment. J Photochem Photobiol B 1994; 22:17-21.
29. Gange R: 8-MOP photosensitization in human skin: Split irradiation studies; in Fitzpatrick T, Forlot P, Pathak M, Urbach F (eds): Psoralens: Past, Present and Future of Photochemoprotection and other biological activities. Paris, Libbey Eurotext, 1989, pp 117-123.